Searchable abstracts of presentations at key conferences in endocrinology

ea0003p111 | Diabetes & Metabolism | BES2002

Counterregulatory hormone responses to hypoglycaemia in type 2 diabetes mellitus - comparison of metformin and sulphonylurea treated subjects

Hoashi S , Cannon D , Kilbane M , Wade B , Kinsley B

The factors affecting counterregulatory (CR) responses to hypoglycaemia in T2DM remain uncertain. Previous studies have suggested an effect of glycaemic control on CR responses in T2DM. Little data exists on the effect of treatment with metformin (MET) vs. Sulphonylurea (SUL) on the CR responses to hypoglycaemia in T2DM.To date, we have performed stepped hypoglycaemic hyperinsulinaemic clamp studies (2-4 mU/kg/min) on 5 subjects treated with MET (Age 50....

ea0034p3 | Bone | SFEBES2014

The utility of bone turnover markers in Paget's disease of bone

Hannon Mark J , Frizelle Isolda M , Kilbane Mark , McKenna Malachi J

Bone turnover markers (BTMs) may have a role in assessing bone turnover and response to intervention in Paget’s disease. We examined the clinical utility of bone turnover markers at diagnosis through analysis of our database of patients with radiographically confirmed Paget’s disease.We identified 36 patients (20 men); mean age at diagnosis was 71.6 years (range 54–84). Radionuclide imaging identified that 64% had polyostotic disease, with...

ea0025p11 | Bone | SFEBES2011

Bone turnover markers in patients on aminobisphosphonate therapy for osteoporosis

Crowley R K , Brady J J , Kilbane M , McKenna M J

Aminobisphosphonates impair osteoclast cell function and reduce bone remodelling rate. It has been speculated that atypical femoral fractures in patients on bisphosphonates are the result of impaired bone remodelling.The primary aim of this prospective study was to assess levels of bone remodelling in patients with osteoporosis on aminobisphosphonate therapy by measurement of bone turnover markers. The secondary aim was to assess the adequacy of concomit...